Center for Cancer Immune Therapy (CCIT); Department of Hematology; Copenhagen University Hospital Herlev; Herlev, Denmark.
Oncoimmunology. 2013 Sep 1;2(9):e26014. doi: 10.4161/onci.26014. Epub 2013 Sep 26.
T lymphocytes can mediate the destruction of cancer cells by virtue of their ability to recognize tumor-derived antigenic peptides that are presented on the cell surface in complex with HLA molecules and expand. Thus, the presence of clonally expanded T cells within neoplastic lesions is an indication of ongoing HLA-restricted T cell-mediated immune responses. Multiple tumors, including renal cell carcinomas (RCCs), are often infiltrated by significant amounts of T cells, the so-called tumor-infiltrating lymphocytes (TILs). In the present study, we analyzed RCC lesions (n = 13) for the presence of expanded T-cell clonotypes using T-cell receptor clonotype mapping. Surprisingly, we found that RCCs comprise relatively low numbers of distinct expanded T-cell clonotypes as compared with melanoma lesions. The numbers of different T-cell clonotypes detected among RCC-infiltrating lymphocytes were in the range of 1-17 (median = 5), and in several patients, the number of clonotypes expanded within tumor lesions resembled that observed among autologous peripheral blood mononuclear cells. Moreover, several of these clonotypes were identical in TILs and PBMCs. Flow cytometry data demonstrated that the general differentiation status of CD8 TILs differed from that of circulating CD8 T cells. Furthermore, PD-1 and LAG-3 were expressed by a significantly higher percentage of CD8 RCC-infiltrating lymphocytes as compared with PBMCs obtained from RCC patients or healthy individuals. Thus, CD8 TILs display a differentiated phenotype and express activation markers as well as surface molecules associated with the inhibition of T-cell functions. However, TILs are characterized by a low amount of expanded T-cell clonotypes.
T 淋巴细胞能够通过识别与 HLA 分子结合并在细胞表面呈递的肿瘤衍生抗原肽来介导癌细胞的破坏,并进行扩增。因此,肿瘤病变中存在克隆扩增的 T 细胞表明正在进行 HLA 限制的 T 细胞介导的免疫反应。包括肾细胞癌 (RCC) 在内的多种肿瘤通常被大量 T 细胞浸润,这些 T 细胞被称为肿瘤浸润淋巴细胞 (TILs)。在本研究中,我们使用 T 细胞受体克隆型图谱分析了 RCC 病变 (n = 13) 中是否存在扩增的 T 细胞克隆型。令人惊讶的是,与黑色素瘤病变相比,我们发现 RCC 包含的扩增 T 细胞克隆型数量相对较少。在 RCC 浸润淋巴细胞中检测到的不同 T 细胞克隆型的数量在 1-17 个之间(中位数=5),在几个患者中,肿瘤病变内扩增的克隆型数量与在自体外周血单核细胞中观察到的数量相似。此外,这些克隆型中的几个在 TILs 和 PBMCs 中是相同的。流式细胞术数据表明,CD8 TILs 的一般分化状态与循环 CD8 T 细胞不同。此外,与从 RCC 患者或健康个体获得的 PBMCs 相比,PD-1 和 LAG-3 在 CD8 RCC 浸润淋巴细胞中的表达比例明显更高。因此,CD8 TILs 表现出分化的表型,并表达激活标志物以及与 T 细胞功能抑制相关的表面分子。然而,TILs 的特征是扩增的 T 细胞克隆型数量较少。